NCT05139719View on ClinicalTrials.gov

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Interventions
DRUG

HEC585 dose A

taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage

DRUG

HEC585 dose B

taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage

DRUG

Placebo

taking Placebo orally once daily, up to 24 weeks in main stage

Trial Locations (1)

Unknown

RECRUITING

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY